These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2374370)

  • 1. Atypical type III hyperlipoproteinemia in a patient with Ig A myelomatosis.
    Feussner G; von Hodenberg E; Ziegler R
    Klin Wochenschr; 1990 May; 68(10):526-32. PubMed ID: 2374370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
    Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
    Breier C
    Wien Klin Wochenschr Suppl; 1986; 167():1-16. PubMed ID: 3458343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
    Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
    J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelomatosis with type III hyperlipoproteinemia: clinical and metabolic studies.
    Cortese C; Lewis B; Miller NE; Peyman MA; Rao SN; Slavin B; Sule U; Turner PR; Utermann G; Wing AJ; Weight M; Wootton R
    N Engl J Med; 1982 Jul; 307(2):79-83. PubMed ID: 6283345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Remnant hyperlipidemia].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():112-8. PubMed ID: 11347041
    [No Abstract]   [Full Text] [Related]  

  • 7. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).
    Sandholzer C; Feussner G; Brunzell J; Utermann G
    J Clin Invest; 1992 Nov; 90(5):1958-65. PubMed ID: 1430218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
    Gregg RE; Ghiselli G; Brewer HB
    J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
    Ehnholm C; Mahley RW; Chappell DA; Weisgraber KH; Ludwig E; Witztum JL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5566-70. PubMed ID: 6591204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
    Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
    Stuyt PM; Demacker PN; van't Laar A
    Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute dyslipoproteinemia induced by interleukin-2: lecithin:cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies.
    Kwong LK; Ridinger DN; Bandhauer M; Ward JH; Samlowski WE; Iverius PH; Pritchard H; Wilson DE
    J Clin Endocrinol Metab; 1997 May; 82(5):1572-81. PubMed ID: 9141552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective deficiency of hepatic triglyceride lipase in uremic patients.
    Mordasini R; Frey F; Flury W; Klose G; Greten H
    N Engl J Med; 1977 Dec; 297(25):1362-6. PubMed ID: 200841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe type III hyperlipoproteinemia in two patients maintained on chronic hemodialysis.
    Feussner G; Bommer J; Ziegler R
    Klin Wochenschr; 1990 Jan; 68(2):65-70. PubMed ID: 2319734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.
    Goldberg IJ; Le NA; Paterniti JR; Ginsberg HN; Lindgren FT; Brown WV
    J Clin Invest; 1982 Dec; 70(6):1184-92. PubMed ID: 7174789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune hyperlipidemia in a patient. Atherosclerotic course and chaning immunoglobulin pattern during 21 years of study.
    Lewis LA; deWolfe VD; Butkus A; Page IH
    Am J Med; 1975 Aug; 59(2):208-18. PubMed ID: 168771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial type V hyperlipoproteinemia with hyper-remnant-like particle-cholesterol accompanied with apolipoprotein E3/E4 phenotype.
    Nagai T; Tomizawa T; Saito T; Nakano T; Nakajima K; Mori M
    Intern Med; 1996 May; 35(5):388-91. PubMed ID: 8797053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment.
    Brewer HB; Zech LA; Gregg RE; Schwartz D; Schaefer EJ
    Ann Intern Med; 1983 May; 98(5 Pt 1):623-40. PubMed ID: 6846977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.